Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

encouraging for the prospects of ANA598 contributing to improved long-term treatment outcomes as measured by SVR."

In the ongoing Phase II study, patients are to receive ANA598 or placebo, added to SOC, for 12 weeks, after which they are to continue receiving SOC alone for 12 or 36 additional weeks. The results announced today are from a scheduled interim analysis following four weeks of dosing in the first of two planned dose cohorts. 44 patients in the first cohort (34 genotype 1a and 10 genotype 1b) received at least one dose of study medications, 29 receiving ANA598 and 15 receiving placebo. Two patients who withdrew consent during the first week of dosing for reasons unrelated to ANA598 are excluded from the analysis of antiviral response but included in the safety database. Reported antiviral response data is as of week 4. Reported safety data is as of an interim analysis date which was reached shortly after the last enrolled patient completed four weeks of dosing, and includes information through week 4 for all patients plus information subsequent to week 4 for those patients who had earlier enrollment dates.


    Preliminary Antiviral Response Assessment

                         total             genotype 1a        genotype 1b
                        patients            patients            patients
                    ANA598    Placebo   ANA598    Placebo   ANA598   Placebo
                     +SOC      +SOC      +SOC      +SOC      +SOC     +SOC
                    ---------------------------------------------------------
    RVR
    ---
    Percentage
     of Patients
     with
     Undetectable     56%        20%      50%        17%       71%       33%
     HCV RNA        (15/27)    (3/15)   (10/20)    (2/12)     (5/7)     (1/3)
     (<15 IU/ml)
     at Week 4

    VIRAL LOAD
     CHANGE
    ----------
    Mean Decline
     in HCV
     RNA (log10
     IU/ml) at
     Week 4            4.1       2.7       4.2       2.4     
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Mar. 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... report to their offering. The global intraoperative ... of 3.5% from 2014 to 2019 It ... a number of forces that favor this market. The ...
(Date:3/31/2015)... 2015 RnRMarketResearch.com adds "Pemphigus ... report of 68 pages with latest updates, data ... The report "Pemphigus - Pipeline Review, H1 2015" ... development for Pemphigus , complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:3/31/2015)... , March 31, 2015  Dr. Renu Razdan ... attending the World Orphan Drug Congress in April to discuss ... regulatory approval process and orphan drugs below: ... recommended to the Ministry of Health that if a new ... authorization can be obtained in India ...
Breaking Medicine Technology:Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market 2015-2019 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By product ... Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), End ... studies the major market drivers, restraints, opportunities and ... Rest of the world (RoW). , The ... $3.58 billion by 2019 from $2.4 billion in ...
(Date:3/31/2015)... Safeware has been recognized ... Central Ohio, an awards program presented by Columbus Business ... the awards program, held on March 10, 2015. These ... health, with outstanding health and wellness initiatives. , ... a healthy environment for their associates. Business Frist, OhioHealth ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... A' Design Award and Competition is pleased ... Daniel Dion has been announced as a winner of ... Devices and Research Equipment Design Competition Category. ... behind the award winning Medical Product design Bruker EVOQ ... direction of Dr. Rohan Thakur and the Bruker team ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... Osteotech, Inc.,(Nasdaq: OSTE ) announced today that third ... third quarter 2006 revenue of $23.4,million. Revenue from Osteotech,s ... for the three months ended September 30,2007 as compared ... for the,third quarter of 2006. Gross margin improved to ...
... 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences,Inc. (TSX: BNC), ... Cameron Groome, Executive,Vice-President, Corporate & Strategic Development, will ... Healthcare Conference in New York City,tomorrow. Mr. Groome ... the Holmes,II Room of the New York Palace ...
... by web cast-, TORONTO, Nov. 6 /PRNewswire-FirstCall/ ... in the research,development and commercialization of pharmaceutical products ... that on,Wednesday, November 7, 2007, at 10:30 a.m. ... and CEO will present a corporate overview of ...
... Elite Books, TUCSON, Ariz., Nov. 5 We all ... the development of Alzheimer,s Disease and heart,disease, along with a ... In her seminal book, The Apo E Gene Diet: ... Body,s Own Genes,(Elite, Hardcover, $27.95, November 1, 2007), Pamela McDonald, ...
... 5 StatSure Diagnostic,Systems, Inc. (OTC Bulletin Board: ... Administration ("FDA"), through its Center for Devices and,Radiological ... Laboratory,Improvements Amendments of 1988 ("CLIA") for an HIV ... The HIV 1/2 product,is marketed and distributed worldwide ...
... offices could ... YORK, Nov. 5 Group Health Incorporated (GHI) and,HIP ... educational seminar in,New York City on November 6 for ... be held at HIP,headquarters, 55 Water St., will provide ...
Cached Medicine News:Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 2Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 3Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 4Health News:Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09 5Health News:Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference 2Health News:Groundbreaking Apo E Gene Diet Linked to Alzheimer's Disease and Heart Disease Prevention 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 2Health News:StatSure's Patented HIV 'Barrel' Technology Receives CLIA Waiver From FDA 3Health News:GHI and HIP Lead Effort to Expand Electronic Health Record System Throughout the City of New York 2
... imaging first with the introduction of the ... This breakthrough platform in imaging offers the ... technology available in a mobile system., ,The ... for mobile imaging systems by providing image ...
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... PS Medical Delta valve is designed ... (CSF) and maintain intraventricular pressure (IVP) ... of patient position. The normally closed ... to positive ventricular pressure. Working with ...
... PS Medical Strata valve is an adjustable ... properties of the valve can be changed ... to minimize overdrainage of cerebrospinal fluid (CSF) ... normal physiologic range, regardless of patient position. ...
Medicine Products: